These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32577501)

  • 1. Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.
    Bergholtz H; Lien TG; Swanson DM; Frigessi A; ; Daidone MG; Tost J; Wärnberg F; Sørlie T
    NPJ Breast Cancer; 2020; 6():26. PubMed ID: 32577501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
    Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD
    Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Omics Marker Analysis Enables Early Prediction of Breast Tumor Progression.
    Xu H; Lien T; Bergholtz H; Fleischer T; Djerroudi L; Vincent-Salomon A; Sørlie T; Aittokallio T
    Front Genet; 2021; 12():670749. PubMed ID: 34149812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer.
    Afghahi A; Forgó E; Mitani AA; Desai M; Varma S; Seto T; Rigdon J; Jensen KC; Troxell ML; Gomez SL; Das AK; Beck AH; Kurian AW; West RB
    Breast Cancer Res; 2015 Aug; 17(1):108. PubMed ID: 26265211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
    Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
    Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic landscape of ductal carcinoma in situ and association with progression.
    Lin CY; Vennam S; Purington N; Lin E; Varma S; Han S; Desa M; Seto T; Wang NJ; Stehr H; Troxell ML; Kurian AW; West RB
    Breast Cancer Res Treat; 2019 Nov; 178(2):307-316. PubMed ID: 31420779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
    Zheng ZY; Elsarraj H; Lei JT; Hong Y; Anurag M; Feng L; Kennedy H; Shen Y; Lo F; Zhao Z; Zhang B; Zhang XH; Tawfik OW; Behbod F; Chang EC
    Breast Cancer Res; 2022 Oct; 24(1):68. PubMed ID: 36258226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.
    Park SY; Seo AN; Jung HY; Gwak JM; Jung N; Cho NY; Kang GH
    PLoS One; 2014; 9(6):e100429. PubMed ID: 24971511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics.
    Hulahan TS; Spruill L; Wallace EN; Park Y; West RB; Marks JR; Hwang ES; Drake RR; Angel PM
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Sieuwerts AM; Doebar SC; de Weerd V; Verhoef EI; Beauford CM; Agahozo MC; Martens JWM; van Deurzen CHM
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer.
    Gennaro M; Meneghini E; Baili P; Bravaccini S; Curcio A; De Santis MC; Lozza L; Listorti C; Di Cosimo S; Sant M; Folli S
    Tumori; 2020 Feb; 106(1):64-69. PubMed ID: 31446852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study.
    Rohan TE; Ginsberg M; Wang Y; Couch FJ; Feigelson HS; Greenlee RT; Honda S; Stark A; Chitale D; Wang T; Xue X; Oktay MH; Sparano JA; Loudig O
    BMJ Open; 2021 Oct; 11(10):e053397. PubMed ID: 34702732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
    Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
    Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.